Vera Therapeutics, Inc. financial data

Symbol
VERA on Nasdaq
Location
Brisbane, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 05 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1907% % 16%
Debt-to-equity 19% % -28%
Return On Equity -51% % -1.6%
Return On Assets -43% % -8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 63,928,066 shares 0.96%
Entity Public Float $1,700,000,000 USD 278%
Common Stock, Value, Issued $64,000 USD 16%
Weighted Average Number of Shares Outstanding, Basic 63,847,055 shares 16%
Weighted Average Number of Shares Outstanding, Diluted 63,847,055 shares 16%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $189,293,000 USD 67%
General and Administrative Expense $80,888,000 USD 155%
Operating Income (Loss) $270,181,000 USD -86%
Nonoperating Income (Expense) $18,239,000 USD 67%
Net Income (Loss) Attributable to Parent $251,943,000 USD -87%
Earnings Per Share, Basic -3 USD/shares -55%
Earnings Per Share, Diluted -3 USD/shares -55%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $57,773,000 USD 112%
Marketable Securities, Current $439,616,000 USD 35%
Other Assets, Current $1,149,000 USD 1.8%
Assets, Current $511,311,000 USD 40%
Property, Plant and Equipment, Net $1,155,000 USD 214%
Operating Lease, Right-of-Use Asset $2,036,000 USD -48%
Assets $517,503,000 USD 40%
Accounts Payable, Current $17,950,000 USD 290%
Employee-related Liabilities, Current $9,715,000 USD 167%
Accrued Liabilities, Current $23,457,000 USD 17%
Liabilities, Current $41,880,000 USD 58%
Operating Lease, Liability, Noncurrent $2,095,000 USD -18%
Liabilities $118,623,000 USD 49%
Accumulated Other Comprehensive Income (Loss), Net of Tax $881,000 USD -16%
Retained Earnings (Accumulated Deficit) $669,768,000 USD -60%
Stockholders' Equity Attributable to Parent $398,880,000 USD 38%
Liabilities and Equity $517,503,000 USD 40%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $54,406,000 USD -61%
Net Cash Provided by (Used in) Financing Activities $1,533,000 USD -99%
Net Cash Provided by (Used in) Investing Activities $15,317,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $37,556,000 USD -260%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $57,773,000 USD 112%
Interest Paid, Excluding Capitalized Interest, Operating Activities $1,581,000 USD 4%
Deferred Tax Assets, Valuation Allowance $106,857,000 USD 50%
Deferred Tax Assets, Gross $107,649,000 USD 49%
Operating Lease, Liability $2,568,000 USD
Payments to Acquire Property, Plant, and Equipment $187,000 USD
Lessee, Operating Lease, Liability, to be Paid $3,224,000 USD -47%
Operating Lease, Liability, Current $473,000 USD -75%
Lessee, Operating Lease, Liability, to be Paid, Year Two $966,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $830,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 33%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $656,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $995,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $38,736,000 USD 41%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $2,048,000 USD 35%
Lessee, Operating Lease, Liability, to be Paid, Year Four $254,000 USD
Operating Lease, Payments $634,000 USD -17%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $85,000 USD 673%
Deferred Tax Assets, Net of Valuation Allowance $792,000 USD 10%
Share-based Payment Arrangement, Expense $33,178,000 USD 86%
Interest Expense $5,816,000 USD 130%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%